At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 159 enrolled
Drug / intervention
GTx-024 +2 moredrug
Likely dose
GTx-024 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in Patients With Cancer
In Brief
A Phase 2 clinical trial evaluating GTx-024 and Placebo for Cachexia. Completed, enrolled 159 participants across 52 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCachexia
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartMay 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedMay 1, 2007
Enrollment StartMay 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.2 years ago
Interventions
GTx-024drug
1 mg GTx 024
GTx-024drug
3 mg GTx-024
Placebodrug
Matching Placebo